Schedule of Financial Assets and Liabilities Measures at Fair Value

The following tables present information about the Company’s financial assets and liabilities measured at fair value on a recurring basis and indicate the level of the fair value hierarchy used to determine such fair values:

	Level 1		Level 2		Level 3		Total
	Fair Value Measurements as of December 31, 2024
	Level 1		Level 2		Level 3		Total
Liabilities:
Acquisition-related contingent consideration obligations	$	—	$	—	$	1,413	$	1,413
Contingent stock consideration		—		—		27		27
Short-term debt - Yorkville		—		—		1,865		1,865
Short-term debt - unsecured senior convertible notes		—		—		620		620
Warrant liability - July 2023 Registered Direct Warrants		—		—		1,115		1,115
Warrant liability - April 2023 Registered Direct Warrants		—		—		1,022		1,022
Warrant liability - May 2022 PIPE Warrants		—		—		505		505
Warrant liability - November 2024 Purchaser Warrants		—		—		278		278
Warrant liability - November 2024 Placement Agent Warrants		—		—		48		48
Warrant liability - Sponsor Warrants		—		—		9		9
Warrant liability - Public Warrants		287		—		—		287
Total fair value liabilities	$	287	$	—	$	6,902	$	7,189

	Level 1		Level 2		Level 3		Total
	Fair Value Measurements as of December 31, 2023
	Level 1		Level 2		Level 3		Total
Assets:
Convertible note receivable	$	—	$	—	$	2,072	$	2,072
Total fair value assets	$	—	$	—	$	2,072	$	2,072

Liabilities:
Acquisition-related contingent consideration obligations	$	—	$	—	$	1,606	$	1,606
Contingent stock consideration		—		—		27		27
Short-term debt - Yorkville		—		—		17,223		17,223
Warrant liability - July 2023 Registered Direct Warrants		—		—		1,529		1,529
Warrant liability - April 2023 Registered Direct Warrants		—		—		1,487		1,487
Warrant liability - May 2022 PIPE Warrants		—		—		708		708
Warrant liability - Sponsor Warrants		—		—		60		60
Warrant liability - Public Warrants		575		—		—		575
Total fair value liabilities	$	575	$	—	$	22,640	$	23,215

Schedule of Convertible Note Valuation Model

Significant inputs for the convertible note valuation model were as follows:

	December 31, 2023
Face value	$	4,000
Coupon rate		12.00% - 17.00%
Stock price	$	0.2
Term (years)		0.51-2.45
Risk-free interest rate		5.47	%
Volatility		n/a

Schedule of Reconciliation of Warrant Liabilities Measured on Recurring Basis

The following table presents a reconciliation of the warrant liabilities measured on a recurring basis using Level 3 inputs for the years ended December 31, 2024 and 2023:

Liabilities:
Balance as of January 1, 2023	$	3,598
April 2023 Registered Direct warrant issuance		4,280
July 2023 Registered Direct warrant issuance		2,645
January 2024 Bridge Loan - Tranche #2 warrant issuance		1,858
November 2024 Purchaser warrant issuance		354
November 2024 Placement Agent warrant issuance		61
Gain recognized in earnings from change in fair value		(6,164	)
Reclassification of warrants from liability classified to equity classified		(2,970	)
Balance as of December 31, 2023	$	4,359

Liabilities:
Balance as of January 1, 2024	$	3,784
January 2024 Bridge Loan - Tranche #2 warrant issuance		1,858
November 2024 Purchaser warrant issuance		354
November 2024 Placement Agent warrant issuance		61
Gain recognized in earnings from change in fair value		(110	)
Reclassification of warrants from liability classified to equity classified		(2,970	)
Balance as of December 31, 2024	$	2,977

Business Acquisition, Contingent Consideration [Line Items]

Schedule of Significant Inputs for Warrants

Significant inputs for the January 2024 Bridge Loan - Tranche #2 Warrants were as follows:

Schedule of January 2024 Bridge Loan

	July 15, 2024			January 16, 2024
		(reclassification)			(issuance)
Common share price	$	3.19		$	2.00
Term to initial exercise date (years) (1)		N/A			0.50
Dividend yield		0	%		0	%
Term (years)		5.0			5.0
Risk-free interest rate		4.00	%		3.90	%
Volatility		112.5	%		107.5	%

(1)

As discussed further in Note 10, the warrants were not exercisable and the exercise price was not set until certain conditions were met. As of July 15, 2024, the warrants became exercisable and no longer contain adjustment provisions to the exercise price that are not indexed to the Company’s own stock. As such, the warrants were adjusted to fair value as of the initial exercise date and then reclassified from liability classified to equity classified.

Business Acquisition, Contingent Consideration [Line Items]

Schedule of Significant Inputs for Warrants

Significant inputs for the Sponsor Warrants are as follows:

	December 31,
	2024	2023
Common share price	$ 2.08	$ 2.47
Exercise price	$ 115.00	$ 115.00
Dividend yield	0%	0%
Term (years)	1.5	2.5
Risk-free interest rate	4.21 %	4.12 %
Volatility	111.4 %	100.7 %

Business Acquisition, Contingent Consideration [Line Items]

Schedule of Convertible Notes Valuation Model

Significant inputs for the unsecured senior convertible notes valuation model were as follows:

	December 31, 2024			November 25, 2024 and December 3, 2024
					(issuance) (1)
Common share price	$	2.08			$2.00 - $3.00
Credit spread		7.6	%		6.9% - 7.2	%
Dividend yield		0	%		0	%
Term (years)		0.90			0.98 - 1.00
Risk-free interest rate		4.20	%		4.30% - 4.40	%
Volatility		50.0	%		50.0	%

(1)

As discussed in Note 10, the securities purchase agreement dated November 25, 2024 provided for multiple closings.

Business Acquisition, Contingent Consideration [Line Items]

Schedule of Reconciliation of Contingent Consideration Obligation Measured on a Recurring Basis

The following table presents a reconciliation of the contingent stock consideration obligation measured on a recurring basis using Level 3 inputs for the years ended December 31, 2024 and 2023:

Balance as of

January 1, 2024

Net

transfers

in to (out of)

Level 3

Purchases,

settlements

and other

net

Fair value

adjustments

Balance as of

December 31,

2024

Liabilities:

Contingent stock consideration

$

27

$

—

$

—

$

—

$

27

Balance as of

January 1, 2023

Net

transfers

in to (out of)

Level 3

Purchases,

settlements

and other

net

Fair value

adjustments

Balance as of

December 31,

2023

Liabilities:

Contingent stock consideration

$

186

$

—

$

—

$

(159

)

$

27